JAMES G. ARMSTRONG, M.D.; RICHARD W. DYKE, M.D., F.A.C.P.; PAUL J. FOUTS, M.D., F.A.C.P.; CHRISTIAN J. JANSEN, M.D.
Derivatives from the flowering periwinkle plant (Vinca rosea Linn.) (1) have been found useful in the treatment of several types of human cancer, including Hodgkin's disease (2, 3). These drugs, vinblastine sulfate (VLB) and vincristine sulfate (VCR), were shown to have embryocidal and teratogenic effects when administered to pregnant golden hamsters (4). However, the dose of VLB or VCR that is toxic for one species will not necessarily be toxic in the same way for another species. In our laboratories, for instance, it has been found that the single intravenous median lethal dose of VLB for dogs is 0.2 mg
ARMSTRONG JG, DYKE RW, FOUTS PJ, et al. Delivery of a Normal Infant During the Course of Oral Vinblastine Sulfate Therapy for Hodgkin's Disease. Ann Intern Med. 1964;61:106–107. doi: https://doi.org/10.7326/0003-4819-61-1-106
Download citation file:
Published: Ann Intern Med. 1964;61(1):106-107.
Results provided by:
Copyright © 2019 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use